Steven Swift to Urinary Bladder, Overactive
This is a "connection" page, showing publications Steven Swift has written about Urinary Bladder, Overactive.
Connection Strength
1.365
-
Treatment outcomes of overactive bladder with combined therapies of botulinum toxin injections and oral agents. Int Urogynecol J. 2021 Oct; 32(10):2803-2806.
Score: 0.731
-
Diary and patient-reported outcomes in patients with severe overactive bladder switching from tolterodine extended release 4 mg/day to solifenacin treatment: An open-label, flexible-dosing, multicentre study. Clin Drug Investig. 2009; 29(5):305-16.
Score: 0.315
-
Transcutaneous posterior tibial nerve stimulation versus extended release oxybutynin in overactive bladder patients. A prospective randomized trial. Eur J Obstet Gynecol Reprod Biol. 2016 Jan; 196:6-10.
Score: 0.126
-
Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder. BJU Int. 2013 Aug; 112(3):373-85.
Score: 0.108
-
Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU Int. 2010 Jan; 105(1):58-66.
Score: 0.084